commonly used term simply refers to the sum total of bile acids present in plasma or serum of mammals. Dr. Evans's suspicion that these are 3-a-hydroxy bile acids is correct. In mammals, the 3-hydroxyl group of bile acid molecules is in the a configuration (5) . The commonly used enzymatic total serum bile acid assays (7) specifically measure 3-a-hydroxy bile acids.
Dr. Evans concluded that the reports of Wang and Stacey (9) and Thompson et al (8) were contradictory concerning the utilization of serum bile acids for detection of hepatotoxicity in rats. Scientifically, these 2 studies are not directly comparable. The studies did not measure the same individual bile acids (Wang and Stacey did not measure tauro-j8muricholic acid and Thompson et al did not measure cholic acid), and different doses and routes of administration of a-naphthyl-isothiocyanate were used. However, both studies showed that the sum total of serum 3-a-hydroxy bile acids was more sensitive than conventional clinical chemistry tests for detection of chemically induced hepatobiliary injury in rats. If an enzymatic total serum bile acid assay is used as a screening test for detection of liver inj ury, identification of the changes in individual bile acids is not necessary. Individual bile acid profiles may provide detailed mechanistic information concerning chemically induced liver injury, but their use as a screening test in nonclinical toxicity and safety studies is not warranted at this time.
The DACC-ASVCP Task Force's recommendation of total serum bile acids as a test for use in nonclinical toxicity and safety studies was based primarily on increased use and experience with this assay in nonclinical safety studies conducted in the United States. Total serum bile acids was recommended as an optional choice in a list of screening tests for evaluation of test material effects on the liver. This approach gives study scientists maximum flexibility and responsibility for making appropriate decisions in selecting blood chemistry tests for safety assessment studies.
Dr. Evans suggests that the task force dismissed omithine decarboxylase (ODC) and omithine carbamoyl transferase (OCT) as routine tests in nonclinical toxicity and safety studies due to analytical complexity alone. This is incorrect. The task force concluded that these 2 tests were impractical for routine use in nonclinical safety assessment studies due to both demanding analytical requirements (1) and marginal testing performance (2) . In a similar published letter, Dr. Evans stated that &dquo;the case for measuring ODC is unproven&dquo; (4). The task force concluded unanimously that this is still the case. Furthermore, Dr. Evans's single reference to the utility of OCT for diagnostic purposes in the dog (6) does not merit a recommendation for routine use of this test in nonclinical toxicity and safety studies involving other species. The task force's recommendations concerning ODC and OCT have not been challenged by scientists from other countries in the ongoing effort for international harmonization of clinical pathology testing (10) . istry tests does not determine the utility and success of clinical pathology testing in nonclinical safety assessment studies. In essence, interpretation of clinical pathology tests is best conducted by examination of a variety of clinical laboratory tests to identify characteristic patterns of changes. This approach enhances the probability and certainty of detecting test material effects and understanding their biological significance for safety assessment. The DACC-ASVCP task force recommendations for clinical pathology testing are minimum recommendations, not limits. The optional test selection approach for evaluation of the test material effects on the liver gives study scientists maximum flexibility for routine test selection and additional testing if necessary.
